UK Public Sector Contracts & Tenders

Radiation Protection Advisory Service NHS Blood & Transplant (NHSBT) intends to undertake a procurement tender exercise for the provision of a Radiation Protection Advisory (RPA) and Radiological Waste Advisory (RWA) service. NHSBT (England) now wishes to commence a formal procurement process and is seeking to engage with suppliers for the provision of RPA/RWA services. The current contract ends in 31/03/2027. NHSBT would like to improve our knowledge of all current RPA/RWA services available in the marketplace. This will aid identification of opportunities and gauge market interest in this field. We require the services to cover the following: - • RPA/RWA services in compliance with Ionising Radiation Regulation 2017 (IRR17). • RPA/RWA services in compliance with Environmental Permitting Regulations 2016 (EPR16). • RPA/RWA services in compliance with NaCTSO Security Requirements Document (SRD) 2024. • Industrial irradiation continuing consent advice to the Health and Safety Executive (HSE). • Technical review of dose mapping reports. • Calibration of radiation monitors. • Annual site visit to each of the centres to audit compliance to regulatory standards. • Advice in the event of an emergency (cover provided 24/7 due to the operational requirements of NHSBT). It is NHSBT's intention to hold pre-procurement supplier engagement meetings the week of May 5rth 2026 to June 5th 2026. the meetings will be held remotely, the dates are to be confirmed. To enable NHSBT to finalise arrangements (e.g. send meeting details and agree time slots) for the meeting’s, interested organisations are required to send an expression of interest via email to Sahithi Bandi - sahithi.bandi@nhsbt.nhs.uk no later than 17:0 hrs (GMT) on 29/05/2026. This should include a list of your potential attendees and a brief overview (or a website link) of the Goods / Services which might be offered. No business whatsoever is guaranteed under any resulting framework agreement or contract, and there is no guarantee that any framework agreement or contract will be put in place in relation to this notice. No compensation etc. will be paid if a tender or resulting framework agreement is withdrawn for any reason. Bidders should take part in this process only on the basis that they fully understand and accept this position. It should be noted that this procurement exercise may allow other Health authorities to use any agreements awarded.

NHS Blood and Transplant (NHSBT) is undertaking preliminary market engagement to inform its procurement and commercial strategy for future logistics services, including courier transport and associated logistics requirements supporting NHSBT’s supply chain. This engagement forms part of NHSBT’s wider market engagement and commercial planning for future logistics services and is intended to further inform the scope, delivery model and procurement approach for any future opportunity. This engagement is intended to help inform the shape of the opportunity and should not be taken to indicate that NHSBT has selected any particular solution, structure or supplier approach. NHSBT currently supports inhouse fleet with a multi-supplier model for courier logistics services, with separate contracts and arrangements supporting the collection, transport and delivery of blood and blood components, plasma, organs, tissues, samples, clinical materials and associated support functions. This varied approach has opportunities to improve: • co-ordination and integration across courier operations; • resilience in some services or locations; • service levels; • reporting and performance monitoring; NHSBT is considering future delivery model options in order to support: • improved operational efficiency and resilience through greater co-ordination across NHSBT fleet and third-party logistics services; • an enhanced solution for dynamic planning across all operations; • consistent service standards across courier operations and locations; • simplified governance and accountability; • enhanced data visibility and performance insight; and • improved value for money through a more co-ordinated and effective service approach. The purpose of this preliminary market engagement is to: • provide background and context to the proposed procurement; • test the proposed scope and potential delivery model options; • better understand market capability, capacity and key risks; • understand potential mobilisation timetable from potential suppliers to ensure the estimated procurement timetable is realistic and to minimise transition risk; • obtain supplier insight on operating models, service integration, mobilisation, resilience, transport planning solutions including dynamic planning, data visibility, governance, commercial arrangements and performance management; and • inform NHSBT’s future commercial strategy and procurement approach. Areas which may be in scope for discussion as part of this engagement include: • scheduled and ad hoc transport; • courier and urgent response services; • specialist clinical logistics; • national and/or regional courier logistics; • control tower, visibility and booking systems; • contingency for “shock” events; • mobilisation, continuity and service resilience; and • 3rd party storage and warehousing to support inhouse provision.

The Clinical Biotechnology Centre at NHS Blood and Transplant is an MHRA-licensed facility for the manufacture of investigational medicinal products, including advanced therapy medicinal products (ATMPs) and other biotechnology products such as plasmid DNA, viral vectors, and therapeutic proteins. The organisation intends to initiate a procurement process for the supply of advanced, high-performance, and cost-effective endonucleases to support the removal of nucleic acids from ATMPs, particularly gene therapy vectors, including adeno-associated viral (AAV) vectors and lentiviral vectors. The endonuclease must exhibit non-specific nuclease activity against a broad range of nucleic acid substrates, including DNA, RNA, plasmid DNA, synthetically produced DNA, enzymatically produced DNA, and other nucleic acid modalities used in viral vector manufacturing. The enzyme should retain activity under physiological pH and salt conditions, while also maintaining high enzymatic performance across a broad pH and salt concentration range. Demonstrated suitability for use in viral vector manufacturing processes employing HEK293 suspension cells cultured in stirred-tank bioreactors will be considered an advantage. Suppliers should also demonstrate that residual endonuclease can be efficiently removed from the viral vector product using a defined set of purification methods commonly applied in bioprocessing. A key requirement is the availability of GMP-qualified and validated analytical assays for the quantification of residual endonuclease at different stages of the manufacturing and purification process. The supplier must provide such assays either directly or through authorised analytical service providers. The supplier should be able to provide endonuclease in multiple quality grades, including R&D grade, GMP-compatible grade, and GMP-qualified grade. It is also essential that these materials are available in quantities suitable for small, medium and large-scale production. Suppliers must provide comprehensive technical and scientific documentation to support the quality attributes and performance characteristics of the endonuclease. Enzymatic activity should be demonstrated using appropriate standards or reference materials relevant to viral vector manufacturing. Overall, the endonuclease must be highly efficient, scalable, and cost-effective, and suitable for the manufacture of clinical-grade viral vectors. Appropriate analytical methods must also be available to support testing of product quality and residual endonuclease levels in drug products intended for human clinical use, in accordance with applicable national and international regulatory requirements.

Supplier to carry out on each of its CMT Cleanrooms. Periodic, specialist deep cleaning is required, supplemental to in-house cleaning and disinfection regimes to ensure that the interior of the CMT Cleanrooms are maintained in a sufficient state of cleanliness in order to achieve ISO14644/ EUGMP standards as required by the regulatory authorities. The deep cleaning detailed in this specification covers the interior of the CMT Cleanrooms only.

This is a pipeline notice in accordance with the requirements of the Procurement Act 2024 and associated regulations and is for information only - it is NOT a call for competition. Collaborating Blood Establishment / Participating Authorities "the Authorities": NHS Blood and Transplant (NHSBT), Welsh Blood Service (WBS), Scottish National Blood Transfusion Service (SNBTS), Northern Ireland Blood Transfusion Service (NIBTS), Irish Blood Transfusion Service (IBTS), Australian Red Cross Lifeblood (ARCL); New Zealand Blood Service (NZBS); NHS Blood and Transplant (NHSBT) is looking to establish a Framework Agreement for primary blood packs, ancillary blood processing packs, sample pouches, additive solutions and automated/semi-automated blood processing technology to commence in 2027. The 8-year Open Framework Agreement ceiling value is £1,141,000,000, this being the maximum spend over the term. The Framework will be between NHS Blood and Transplant and the awarded Suppliers. Call-off Contracts will be between the individual blood establishments and the Supplier. The anticipated Lot Structure for this procurement is set out as follows: Lot 1: Blood Packs *Primary Whole Blood Collection Lot 2: Ancillary Blood Processing Systems *Ancillary Blood Processing Systems for component development *Sample Pouch for Quality Monitoring of components Lot 3: Additive Solutions *For the suspension of pooled and apheresis platelets (Platelet Additive Solution) *For the washing and re-suspension of ‘washed’ platelets *For the washing and storage of red blood cells Lot 4: Automated or Semi-Automatic Blood Processing

Portable unit. Modular design that can incorporate multiple charging points and be upgraded.